XOMA Royalty Declares Quarterly Preferred Stock Dividends
Rhea-AI Summary
XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividend payments for its preferred stockholders. The company's Board of Directors has authorized dividends for two series of preferred stock:
- Holders of 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share
- Holders of 8.375% Series B Cumulative Perpetual Preferred Stock depositary shares (Nasdaq: XOMAO) will receive $0.52344 per depositary share, with each depositary share representing 1/1000 of a preferred share
Both dividend payments are scheduled for April 15, 2025, with a record date of April 3, 2025.
Positive
- Consistent dividend payments maintained for preferred stockholders
- Attractive dividend yields: 8.625% for Series A and 8.375% for Series B preferred stocks
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, XOMA gained 0.77%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:
Holders of the
Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s
The preferred dividends will be paid on or about April 15, 2025, to respective holders of record at the close of business on April 3, 2025.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel
| Investor contact: Juliane Snowden XOMA Royalty Corporation +1-646-438-9754 juliane.snowden@xoma.com | Media contact: Kathy Vincent KV Consulting & Management +1-310-403-8951 kathy@kathyvincent.com |
FAQ
What is the dividend amount for XOMA Series A preferred stock (XOMAP) in Q2 2025?
When is the payment date for XOMA's preferred stock dividends announced in March 2025?
What is the dividend amount for XOMA Series B preferred stock (XOMAO) depositary shares?
What are the dividend yields for XOMA's Series A and Series B preferred stocks?
